Encoded Therapeutics secured a $275 million Series F to push ETX101, its lead genetic medicine for SCN1A-positive Dravet syndrome, into clinical trials. The financing funds registration-directed studies in young children, expands into adolescents, and supports scaling internal manufacturing rather than relying on contractors. The round also advances a second program, ETX301, a gene therapy for post-amputation neuroma pain, toward a planned 2027 IND filing. Co-lead backing included GV and additional healthcare-focused capital, with the syndicate signaling confidence in durability and manufacturing readiness. For the sector, the deal reinforces how investors are funding gene-therapy platform scale-up alongside clinical execution—especially in rare pediatric neurology.